Clinical trial
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
NCT07259317 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
- Lead sponsor
- Corcept Therapeutics
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 27, 2026
- Completion date
- September 30, 2027
- Enrollment
- 80 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.